Amphastar Pharmaceuticals Inc - Company Profile
Powered by 
All the sales intelligence you need on Amphastar Pharmaceuticals Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Amphastar Pharmaceuticals Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Amphastar Pharmaceuticals Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Amphastar Pharmaceuticals Inc (Amphastar) is a biopharmaceutical company. It focuses on developing, manufacturing, and marketing generic and proprietary injectable, intranasal and inhalation products. The company also sells insulin-active pharmaceutical ingredient products. The company’s product portfolio consists of glucagon nasal powder, enoxaparin sodium injection, cosyntropin injection, naloxone hydrochloride injection, phytonadione injection, lidocaine jelly, amphadase hyaluronidase injection and primatene mist, among others. Amphastar offers its products to hospitals, long-term care facilities, alternative care sites, clinics, and doctors’ offices, and retail pharmacies. The company distributes its products through specialty distributors, wholesalers and retailers in the US, France and China. Amphastar is headquartered in Rancho Cucamonga, California, the US.
Headquarters
United States of America
Address
11570 6th St, Rancho Cucamonga, California, 91730
Website
www.amphastar.com
Telephone
1 909 9809484
No of Employees
2,028
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
AMPH (NASD)
Revenue (2024)
$732.0M
13.6%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
16%
(2024 vs 2023)
Market Cap*
$797.2M
Net Profit Margin (2024)
XYZ
2.1%
(2024 vs 2023)
* As of and is in US$
Amphastar Pharmaceuticals Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Atropine Sulphate Injection, USP | Amphadase |
| Amphadase (Hyaluronidase injection, USP) | Baqsimi |
| Baqsimi (glucagon) Nasal Powder | Cortrosyn |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Contracts/Agreements | In January, the company entered into a license agreement with Nanjing Hanxin Pharmaceutical Technology Co Ltd for the development, and commercialization of fully synthetic corticotropin compound. |
| 2025 | Regulatory Approval | In December, the company received approval from the US FDA for teriparatide injection. |
| 2025 | Contracts/Agreements | In August, the company entered into an agreement with Nanjing Anji Biotechnology Co Ltd for the development, manufacturing, and commercialization of three proprietary peptides in the US and Canada. |
Competitor Comparison
| Key Parameters | Amphastar Pharmaceuticals Inc | Pfizer Inc | Sanofi | Eli Lilly and Co | Teva Pharmaceutical Industries Ltd |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | France | United States of America | Israel |
| City | Rancho Cucamonga | New York City | Paris | Indianapolis | Tel Aviv |
| State/Province | California | New York | Ile-de-France | Indiana | Tel Aviv |
| No. of Employees | 2,028 | 81,000 | 84,587 | 47,000 | 37,000 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Jack Yongfeng Zhang, Ph.D. | President; Chief Scientific Officer; Chief Executive Officer; Director | Executive Board | 2020 | 78 |
| William J. Peters | Treasurer; Director; Chief Financial Officer; President - International Medication Systems, Limited; Executive Vice President - Finance | Executive Board | 2022 | 57 |
| Mary Ziping Luo, Ph.D. | Chief Operating Officer; Chairwoman; Chief Scientist | Executive Board | 2005 | 75 |
| Jacob Liawatidewi | President - Amphastar France Pharmaceuticals, S.A.S.; Director; Executive Vice President - Sales and Marketing, and Corporate Administration Center | Executive Board | 2022 | 51 |
| Tony Marrs | President - Armstrong Pharmaceuticals; Executive Vice President - Clinical Operations; Executive Vice President - Regulatory Affairs | Senior Management | 2018 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer